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ABSTRACT Although pyrazinamide (PZA) is a key component of ﬁrst- and second-
line tuberculosis treatment regimens, there is no gold standard to determine PZA re-
sistance. Approximately 50% of multidrug-resistant tuberculosis (MDR-TB) and over
90% of extensively drug-resistant tuberculosis (XDR-TB) strains are also PZA resistant.
pncA sequencing is the endorsed test to evaluate PZA susceptibility. However, mo-
lecular methods have limitations for their wide application. In this study, we stan-
dardized and evaluated a new method, MODS-Wayne, to determine PZA resistance.
MODS-Wayne is based on the detection of pyrazinoic acid, the hydrolysis product of
PZA, directly in the supernatant of sputum cultures by detecting a color change fol-
lowing the addition of 10% ferrous ammonium sulfate. Using a PZA concentration of
800 g/ml, sensitivity and speciﬁcity were evaluated at three different periods of in-
cubation (reading 1, reading 2, and reading 3) using a composite reference standard
(MGIT-PZA, pncA sequencing, and the classic Wayne test). MODS-Wayne was able to
detect PZA resistance, with a sensitivity and speciﬁcity of 92.7% and 99.3%, respec-
tively, at reading 3. MODS-Wayne had an agreement of 93.8% and a kappa index of
0.79 compared to the classic Wayne test, an agreement of 95.3% and kappa index of
0.86 compared to MGIT-PZA, and an agreement of 96.9% and kappa index of 0.90
compared to pncA sequencing. In conclusion, MODS-Wayne is a simple, fast, accurate,
and inexpensive approach to detect PZA resistance, making this an attractive assay
especially for low-resource countries, where TB is a major public health problem.
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Tuberculosis (TB) is still an endemic disease in low-income countries, and in 2017,there were an estimated 10 million new TB cases and 1.3 million deaths (1). One of
the most important threats to TB control is the increasing rate of multidrug-resistant
(MDR) and extensively drug resistant (XDR) TB cases (1). Care in selecting appropriate
treatment regimens is therefore vital. Pyrazinamide (PZA) is the only drug with different
activity in vivo and in vitro (2). Its importance is based on its in vivo sterilizing effect that
permits killing of persistent bacilli (3). PZA is frequently used in both ﬁrst- and
second-line treatment regimens (1, 4, 5). The incorporation of PZA into TB treatment
regimens in the 1960s enabled the duration of ﬁrst-line treatment to be reduced from
9 to 12 months to 6 months (6).
Despite its clinical importance, its mechanism of action and of resistance remain
unknown (7). Brieﬂy, PZA is a prodrug that enters the bacilli by passive diffusion. In the
cytosol, it is hydrolyzed into pyrazinoic acid (POA), the active molecule against M.
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tuberculosis, by a reaction catalyzed by the pyrazinamidase (PZase) enzyme. POA is then
expelled by an efﬂux system into the acidic environment (pH 5.5) where it is proto-
nated. This reenters the bacteria and releases the proton into the cytosol. Repetition of
this cycle results in the accumulation of intracellular POA plus acidiﬁcation of the
cytoplasm, which is lethal to the mycobacteria (2, 8–10).
Although PZA is a cornerstone in TB drug regimens, microbiological drug suscep-
tibility testing (DST) is not routinely performed due to notorious technical limitations.
However, there is evidence that the empirical use of PZA in patients with PZA resistance
is associated with higher mortality rates (11), and therefore, obtaining a method of
establishing PZA resistance would represent a signiﬁcant advantage in the manage-
ment of TB patients. Technical challenges include the inﬂuence of inoculum size, long
turnaround time, and poor reproducibility test (12, 13). Crucially, DST for PZA requires
an acidic culture medium (5, 14, 15), but acidity inhibits M. tuberculosis growth in vitro
(16). Current microbiological DSTs utilize a less acidic pH compensated by a higher
concentration of PZA (17). For example, Bactec Mycobacterial Growth Indicator Tube
960 PZA (MGIT-PZA), the assay most recently endorsed by the WHO for this purpose,
uses a pH of 6.0 and critical concentration of 100 g/ml PZA. However, this PZA
concentration is lower than that expected for a pH of 6.0, and this may account for false
reporting of PZA resistance (17–19). Moreover, the reproducibility of this method is
poor (20–22).
Molecular DSTs are based on the detection of mutations in the putative promoter
and gene sequence of pncA, which encodes PZase. These mutations often impair PZase
activity and are the main cause of PZA resistance (4, 20, 23). However, the sensitivity of
molecular tests is varied (45.7% to 93.0%), and speciﬁcity is low (10, 20, 24, 25), as not
all mutations equally affect PZase activity (4, 20, 26). In addition, the absence of
mutation hot spots, low frequency of mutations, a wide repertory of pncA gene
mutations, and the high cost of sequencing limit their use (4, 27).
The classic Wayne test is a biochemical colorimetric test. It is inexpensive and simple
to perform and uses an agar culture medium containing 100 g/ml PZA at pH 6.4 to 6.8
(28, 29). PZA-susceptible strains release POA near neutral pH, and in the presence of
ferrous ammonium sulfate (SAF), this produces a pink complex that can be visualized
(reported as positive). The absence of a color change indicates the absence of POA, and
therefore, PZA resistance (reported as negative) (28). The classic Wayne test has a
sensitivity of 75.6 to 95.7% and speciﬁcity of 88.7 to 97% (8, 14, 29–31). However, a long
turnaround time due to very low mycobacterial growth rates, the requirement of a
large inoculum size, and subjective interpretation make this assay impractical for
routine clinical use (8, 29, 30).
More recently, a quantitative variant of the Wayne test has been reported (8) in
which the concentration of POA produced by M. tuberculosis in citrate buffer at pH 7.0
is determined spectrophotometrically. Sensitivity and speciﬁcity were high (96.0% and
97.4%, respectively), but this assay also suffers from technical restrictions.
The microscopic-observation drug susceptibility (MODS) assay can accurately diag-
nose TB and MDR-TB in liquid culture medium after 5 to 21 days (32, 33). It has several
advantages, as follows: it can be performed directly from sputum, the cost is low, little
additional equipment or training is required, and the turnaround time is short (32–36).
The MODS assay has both a sensitivity and speciﬁcity approaching 100% and very good
agreement with MGIT for the detection of rifampin and isoniazid susceptibility. Most
recently, the MODS assay has been extended to accurately perform DST for second-line
drugs (capreomycin, ciproﬂoxacin, cycloserine, ethambutol, ethionamide, kanamycin,
para-aminosalicylic acid, amikacin, oﬂoxacin, moxiﬂoxacin, and streptomycin) (33, 37),
but susceptibility testing for PZA has not yet been achieved.
Here, we present for the ﬁrst time a colorimetric-qualitative adaptation of the MODS
assay to determine PZA resistance directly from sputum samples. Because of the lack of
a reference method test, the results of this assay have been compared to a composite
reference standard (13, 38) composed of results of MGIT-PZA, pncA sequencing, and the
classic Wayne test to estimate sensitivity and speciﬁcity.
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MATERIALS AND METHODS
Setting and samples. For this study, 193 sputum samples were selected from a larger study
conducted in 2015 to 2016. The remaining samples were obtained from TB patients enrolled in the
National TB Strategy treatment program at the Hospital Nacional Dos de Mayo, Lima, Peru, and from the
Regional Tuberculosis Reference Laboratory, Callao, Lima, Peru. All sputum samples selected for this
study were positive for TB according to the MODS assay. Given that MDR-TB isolates have a 50% chance
of also being resistant to PZA (3, 14, 29), in order to select a high number of PZA-resistant sputum
samples for evaluation, we selected approximately 50% of specimens that were MDR and monoresistant
to isoniazid or rifampin and 50% of non-MDR specimens. Data concerning patient age, sex, and TB
treatment were collected. Ethical approval was obtained from the Universidad Peruana Cayetano
Heredia, Lima, Peru.
MODS for MDR-TB detection. Sputum samples were decontaminated according to the standardized
MODS protocol (39). Brieﬂy, 2 ml of the sample was mixed with 2 ml fresh 2% N-acetyl-L-cysteine-sodium
hydroxide (NALC-NaOH) by vortexing and then incubated at room temperature for 15 min. Next, 10 ml
phosphate buffer was added to neutralize the solution. The solution was centrifuged at 3,000 g for 15
min. The pellet was resuspended in 15 ml Middlebrook 7H9 culture medium (Fisher Scientiﬁc, USA) with
oleic acid-albumin-dextrose-catalase (OADC; Fisher Scientiﬁc) and polymixin-B-amphotericin-B-nalidixic-
acid-trimethoprim-azlocillin (PANTA; BD, USA) enrichment.
Testing for MDR was performed in a 24-well plate following a modiﬁed MODS protocol (39). Brieﬂy,
100 l of 7H9 medium was dispensed into the ﬁrst two wells of each column on the plate. Next, 100 l
of drug solution (ﬁnal concentrations, 0.4 g/ml isoniazid [INH], 1.0 g/ml rifampin [RIF]) was dispensed
into the next two wells of each column. Nine hundred microliters of decontaminated sample was then
added to each well. The plate was placed in a resealable bag (Ziploc) and incubated at 37°C for a
maximum of 21 days. The plate was read according to the MODS protocol using an inverted light
microscope. A positive culture was reported when cording growth of M. tuberculosis was observed in
either or both of the control wells (39). For positive samples, the INH- and RIF-containing wells were read
and reported on the same day, and visualization of growth was reported as resistance to the corre-
sponding drug.
Composite reference standard for PZA susceptibility determination. Given the lack of a reference
method to determine PZA resistance, every M. tuberculosis isolate was processed using three different
assays, MGIT-PZA, pncA sequencing, and the classic Wayne test. A PZA-resistant sample was deﬁned as
having resistance according to at least two of the three assays, and a PZA-susceptible sample was
deﬁned as susceptibility according to at least two of the three assays (15). To perform these tests, a pure
isolate was required; an aliquot from a control well of the MODS assay was inoculated onto plates
containing OADC-supplemented 7H11 medium (Fisher Scientiﬁc, USA). These plates were incubated at
37°C for 14 to 21 days, after which each plate was evaluated by microscopy to detect M. tuberculosis
growth. These colonies were used in subsequent assays.
MGIT-PZA was performed according to the manufacturer’s instructions. Brieﬂy, a suspension with
turbidity equivalent to 0.5 McFarland was prepared. The suspension was diluted in physiological saline
at a 1:5 and 1:10 ratio, 0.5 ml of which was added to the susceptibility test tube and control tube,
respectively. In addition, PZA was added to the susceptibility test tube at a ﬁnal concentration of
100 g/ml. The tubes were incubated in a MGIT 960 system. To obtain results, the ﬂuorescent signal
obtained from the control and the PZA susceptibility tubes were compared over a period of 4 to 21 days.
For pncA sequencing, one full loop of M. tuberculosis culture was suspended in 500 l of Tris-EDTA
buffer at pH 8.0 and inactivated by heating to 80°C for 30 min. Three-millimeter glass beads were added
to the bacterial suspension. DNA extraction was performed using a modiﬁed protinase K-chloroform
protocol, as previously described (40). PCR was performed as follows: 50 l PCR master mix contained 1
PCR buffer (Thermo Scientiﬁc, USA), 2.5 M dinucleoside triphosphates (dNTPs), 1.5 mM MgCl2 (Thermo
Scientiﬁc), 0.5 M primer P1 (5=-GTCGGTCATGTTCGCATCG-3=; from 105 bp upstream of pncA) and primer
P6 (5=-GCTTTGCGGCGAGCGCTCCCA-3=; from 60 bp downstream of pncA) (41), and 0.03 U/l Taq poly-
merase (Thermo Scientiﬁc). The PCR cycling parameters were set to one cycle of 94°C for 4 min, followed
by 30 cycles of 94°C for 45 s, 58°C for 60 s, and 72°C for 60 s, with a ﬁnal step of 94°C for 5 min. The 720-bp
ampliﬁcation products were sequenced using the same primers that were used for PCR. The presence of
mutations in both the pncA gene and the putative promoter was evaluated by pairwise sequence
alignment with the nucleotide sequence of the M. tuberculosis H37Rv reference strain (NCBI RefSeq
accession no. NC_000962.3). Identiﬁed mutations were compared with those reported in the Tubercu-
losis Drug Resistance Mutation Database (42).
The classic Wayne test was performed as described previously (28). Brieﬂy, a heavy loopful of 21-day
M. tuberculosis culture was inoculated onto Dubos culture medium. The tubes were incubated at 37°C for
7 days. For each test round, positive (H37Rv) and negative (DM097) controls were included. For the test
reading, 1 ml 1% SAF (Sigma-Aldrich, USA) was added, and the tubes were inspected for the presence of
a pink band. Where this was not seen, the tubes were incubated at 4°C for an additional 4 h and then
read again, and this was reported as the ﬁnal result; the presence of a pink band indicated a susceptible
strain, and the absence of color indicated a resistant strain.
Acid-fast bacillus smear. In order to explore a potential effect of the bacillary load in sputum with
the MODS-Wayne assay, each sample was evaluated by smear microscopy using Ziehl-Neelsen staining.
The procedure was performed and the slide interpreted according to standard techniques (43).
MODS-Wayne assay. A variant of the MODS assay (MODS-Wayne) was standardized to determine
PZA resistance directly from decontaminated sputum samples. This variant utilizes a Middlebrook 7H9
culture broth enriched with OADC and PANTA (pH 6.8) that favors the growth of M. tuberculosis isolates
MODS-Wayne for PZA Susceptibility Determination Journal of Clinical Microbiology
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in culture. Unlike traditional PZA susceptibility tests, MODS-Wayne does not require an acidic pH because
the goal of the assay is to detect the production of POA from PZA metabolism and not to evaluate PZA
bacterial killing. The neutral pH permits the POA to accumulate in the supernatant where it can be
detected using SAF.
Each decontaminated sample was cultured in 6 wells in a 24-well plate. Nine hundred microliters of
the decontaminated sample was seeded per well. Three wells corresponded to control wells, and the
other 3 wells were designated for PZA addition. As the test is performed using decontaminated sample,
it is possible that the number of viable bacilli, or bacillus viability, could be reduced by stress during the
decontamination process; in order to increase the number of bacilli and/or to improve the viability of
stressed bacteria, the plate was ﬁrst incubated at 37°C with no drug. The plate reading commenced on
day 5 and was then performed every 2 days until day 21, according to the standard MODS protocol (39).
When at least two microcolonies were observed in the control wells, 100 l PZA (8,000 g/ml) (Sigma-
Aldrich, USA) was added to one of the PZA wells (ﬁnal concentration, 800 g/ml). After 3 days and 6 days,
the same volume of PZA was added to one of the remaining PZA wells. Based on previous results, in
order to facilitate the production of a detectable amount of POA by a Wayne reaction, after the addition
of PZA, the samples were incubated for 3 days, during which time the bacilli were able to produce POA.
The nonacidic pH (6.8) prevented the lethal effect of the drug and thus the inhibition of growth, and
these conditions would be expected to maximize the production and accumulation of POA, the pivotal
biomarker of PZA resistance. At the end of this additional period (reported as reading 1 [R1], reading 2
[R2], and reading 3 [R3]) (Fig. 1), 100 l of 10% ferrous ammonium sulfate (Sigma, USA) was added to the
corresponding control and PZA wells, and the color was registered immediately. A positive result was
reported when a pink color was observed in the PZA well but not in the control well, and a negative
result was reported when no color was observed in either the control well or the PZA well (Fig. 2A and
B). Additionally, the level of growth on culture was reported in one of four categories according the
degree of aggregation by microscopy, high growth, regular growth, low growth, and microcolonies, to
evaluate any possible inﬂuence on the MODS-Wayne assay.
RESULTS
Agreement between the dichotomous MODS-Wayne results and the composite
reference standard for each of the three drug incubation periods was estimated using
the Kappa statistic in a 2-by-2 contingency table. The potential effect of bacillary load
or level of growth on the MODS-Wayne results was evaluated using Fisher’s exact test.
For results with a positive association, a proportion test was performed to evaluate
signiﬁcant differences. The sensitivity and speciﬁcity (95% conﬁdence interval [CI]) of
the MODS-Wayne assay compared to those of the consensus reference test were
estimated for each drug incubation period. McNemar’s test was used to determine
signiﬁcant differences between sensitivities and speciﬁcities among MODS-Wayne
results. All statistical tests were reported with 95% conﬁdence intervals and were
performed using Stata version 14.0.
FIG 1 MODS-Wayne plate design. Three samples were evaluated in each plate. One control well was included for
every sample for each reading (R1, R2, and R3). Red arrows represent the 3 days of incubation after pyrazinamide
(PZA) addition. Ferrous ammonium sulfate (SAF) was added after the incubation with PZA.
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Study population. Sputum samples were obtained from 193 patients. The descrip-
tive statistics for the study population are shown in Table 1. Data were missing for the
following ﬁelds: TB treatment (79/193 [40.9%]), age (43/193 [22.3%]), and sex (22/193
[11.4%]).
Of the 193 sputum samples collected, 101 (52.3%) were pansusceptible according to
the MODS assay. Ninety-two samples (47.7%) had growth in the INH- and/or RIF-
containing wells, indicating resistance; of these, 23 samples (11.9%) were monoresistant
to isoniazid, 12 samples (6.2%) were monoresistant to rifampin, and 57 samples (29.5%)
were resistant to both drugs (i.e., MDR).
Composite reference standard for PZA susceptibility determination. According
to MGIT-PZA, 147 samples (76.2%) were PZA susceptible, and 46 samples (23.8%) were
FIG 2 MODS-Wayne results. The intensity of the color is enough to allow discrimination between a
positive (presence of pink color) result (A), and a negative (absence of pink color) result (B), indicating
pyrazinamide (PZA) susceptibility and resistance, respectively.
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resistant. According to the classic Wayne test, 162 samples (83.9%) were PZA suscep-
tible, and 31 samples (16.1%) were resistant. At least one mutation was detected in the
pncA gene in 51/193 samples (26.4%). Forty-seven (92.2%) of the mutations were single
nucleotide polymorphisms, and four samples (2.1%) had a deletion in the pncA gene
(nucleotides 376 to 389 or 456 to 466). SNPs were found at the putative promoter
(A-11G), metal-binding site (D49N, H51R, H57L, H57R, and H71R), and the active site
(D8E). The PZA susceptibility proﬁle was given according to data reported in the
Tuberculosis Drug Resistance Mutation database (42); 154 samples (79.8%) were clas-
siﬁed as PZA susceptible by pncA sequencing. This group included strains with a
wild-type phenotype and with K48T, P62S, and F81S mutations. The rest of the strains
with mutations were reported as PZA resistant (39/193 [20.2%]) (Table 2).
Overall, according to the composite reference standard, 152 samples were reported
as PZA susceptible (78.8%), and 41 samples were reported as PZA resistant (21.2%).
TABLE 1 Description of patients from whom sputum samples were obtaineda
Characteristic No. (%)
Patients
Callao reference lab 162 (83.9)
Hospital Nacional Dos de Mayo 31 (16.1)
Sex
Female 59 (30.1)
Male 113 (58.6)
Data not available 22 (11.4)
Age (yr)
13–22.3 33 (17.1)
22.3–31.5 30 (15.5)
31.5–40.8 27 (13.9)
40.8–50 23 (11.9)
50–59.3 19 (9.8)
59.3–68.5 8 (4.1)
68.5–77.8 6 (3.1)
77.8–87 4 (2.1)
Data not available 43 (22.3)
TB treatment
Never treated 93 (48.2)
Previous or ongoing treatment 21 (10.9)
Data not available 79 (40.9)
aAll samples met the following criteria: minimum volume of 2 ml and positive acid-fast microscopy results
(health center’s results).
TABLE 2Mutations in the putative promoter and pncA gene reported in this studya
Genotype Reported frequency PZA susceptibility proﬁle %
Promoter (A-11G) 1 Resistant 0.5
D49N 1 Resistant 0.5
D8E 2 Resistant 1.0
F81S 2 Susceptible 1.0
H51R 10 Resistant 5.2
H57L 1 Resistant 0.5
H57R 1 Resistant 0.5
H71R 2 Resistant 1.0
I6S 2 Resistant 1.0
K48T 9 Susceptible 4.7
P62S 1 Susceptible 0.5
Q10P 2 Resistant 1.0
Q10R 13 Resistant 6.7
Δ375–389 1 Resistant 0.5
Δ456–466 3 Resistant 1.6
Wild type 142 Susceptible 73.6
aSpeciﬁc mutations are reported along with the strain’s corresponding PZA susceptibility proﬁle according to
the Tuberculosis Drug Resistance Mutation Database.
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Among these, 147 samples (76.2%) were sensitive according to all three tests used, and
29 samples (15.0%) were resistant according to all three tests (Fig. 3). For MDR and
RIF-resistant isolates, 52.6% (30/57) and 58.3% (7/12) were reported as PZA resistant by
the consensus reference test, respectively. In contrast, just 4.0% (4/101) of the pansus-
ceptible isolates were reported as PZA resistant. No PZA resistance was reported in
INH-monoresistant isolates.
Acid-fast bacillus smear. Acid-fast smear testing was positive for 182 samples. Of
these samples, 6.0% (11/182) were reported as paucibacillary (less than 1 bacillus seen
per microscopic ﬁeld), 22.0% (40/182) as 1, 33.5% (61/182) as 2, and 38.5% (70/182)
as 3; 5.7% of the samples (11/193) were smear negative. A trend between bacillary
load and the positivity of MODS-Wayne at the earlier time points was observed;
however, this did not reach statistical signiﬁcance (Fisher’s exact test, P  0.06 for R1,
P  0.081 for R2, and P  0.514 for R3).
MODS-Wayne performance. The proportion of negative results (resistant pattern)
decreased with increasing reading day, from 104/193 (53.9%) to 39/193 (20.2%) (Table
3). By R3, negative results (PZA resistance) were reported in 5/101 (4.95%) of the
pansusceptible isolates, 27/57 (47.4%) of the MDR-TB isolates, and 7/12 (58.3%) of the
RIF-resistant isolates. All INH-resistant isolates (23/23) were reported as positive (PZA
susceptible).
On mycobacterial culture, 50.3% of the total samples (97/193) had a high level of
growth, 30.1% (58/193) had regular growth, 12.4% (24/193) had low growth, and 7.3%
(14/193) had microcolonies only. Similarly to the MODS-Wayne results, the proportion
of positive samples increased as reading day increased for each level of growth
reported (Table 4). A signiﬁcant association was observed between the level of growth
FIG 3 Sample distribution by PZA susceptibility proﬁle. Distribution displayed according to the results
from Bactec MGIT 960 PZA, pncA sequencing, and classic Wayne test. For stacked numerals, the number
of PZA-susceptible isolates is given above the number of PZA-resistant isolates.
TABLE 3 Susceptibility to PZA determined by the MODS-Wayne assay for each reading
daya
Reading
MODS-Wayne results (no. of isolates susceptible or
resistant [% of total])
PZA susceptible PZA resistant
R1 89 (46.1) 104 (53.9)
R2 132 (68.4) 61 (31.6)
R3 154 (79.8) 39 (20.2)
an  193 isolates. With increasing incubation time, the assay reported an increasing proportion of PZA-
susceptible isolates.
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and the positivity with MODS-Wayne assay at R1 (P 0.045) and at R2 (P 0.008) but
not at R3 (P 0.09).
High and regular growth levels were associated with a higher proportion of posi-
tivity in the MODS-Wayne assay at R2 (P 0.0001), but no signiﬁcant association was
observed for samples with low growth or microcolonies (P 0.56 and 0.45, respec-
tively). Conversely, low growth level and microcolonies were associated with a higher
proportion of negative MODS-Wayne results at R1 (P 0.011 and 0.0012, respectively),
but no signiﬁcant association was observed for samples with high and regular growth
(P 0.20 and 0.14, respectively).
Accuracy measures for MODS-Wayne. Results from each reading day were com-
pared to the composite reference standard independently. Sensitivities (true resistant
percentage) in R1, R2, and R3 were similar, ranging from 92.7% to 97.6% (P 0.05).
However, the speciﬁcities showed a broader range, increasing from 57.9% to 99.3%
(Table 5) and with a statistically signiﬁcant difference upon comparison (P 0.05).
As the MODS-Wayne and the classic Wayne assays obey the same principles, they
were directly compared. At day 16, the sensitivity of MODS-Wayne was 93.5% and
speciﬁcity was 93.8%, with an agreement and kappa index of 93.8% and 0.79, respec-
tively (P  0.001). (Data from other time points not shown.) Ten isolates were PZA
resistant according to the MODS-Wayne assay but PZA susceptible according to the
classic Wayne test. When their genotypes were analyzed, nine isolates had mutations
associated with PZA resistance (Q10P, Q10R, H51R, and H57R), and one strain was wild
type.
DISCUSSION
This study shows for the ﬁrst time that an adaptation of the MODS assay combined
with the Wayne test (MODS-Wayne) can accurately determine M. tuberculosis resistance
to PZA directly from AFB smear-positive sputum samples and can achieve this in a
relatively short period of time compared to other PZA DSTs. In addition, it is inexpen-
sive, simple to perform, and requires minimal training of laboratory staff. The MODS-
Wayne assay is based upon the principle that POA is only produced by PZA-susceptible
bacilli, and therefore, detection of POA in the supernatant of a MODS culture through
visual observation of a Wayne colorimetric reaction functions as an accurate proxy for
PZA sensitivity. In contrast with previous efforts to modify MODS for PZA resistance
testing, in this adaptation, after sputum samples are decontaminated, the stressed M.
tuberculosis bacilli are grown at a nonharmful neutral pH, in the absence of any drug
until mycobacterial growth is observed. PZA is only added after this time. The neutral
TABLE 4 Proportion of samples with positive and negative results by MODS-Wayne assay
per reading daya
Level of growth in culture (n)
No. (%) with result by reading day
R1 R2 R3
Positive Negative Positive Negative Positive Negative
Microcolonies (14) 3 (21.4) 11 (78.6) 6 (42.9) 8 (57.1) 9 (64.3) 5 (35.7)
Low growth (24) 8 (33.3) 16 (66.7) 11 (45.8) 13 (54.2) 16 (66.7) 8 (33.3)
Regular growth (58) 25 (43.1) 33 (56.9) 43 (74.1) 15 (25.9) 50 (86.2) 8 (13.8)
High growth (97) 53 (54.6) 44 (45.4) 72 (74.2) 25 (25.8) 79 (81.4) 18 (18.6)
aAn increase in the number of samples with positive results was observed along the reading days.
TABLE 5 Performance of MODS-Wayne assay compared to composite standarda
Reading day
Sensitivity Speciﬁcity
% (no. of isolates/total no. of isolates) 95% CI (%) % (no. of isolates/total no. of isolates) 95% CI (%)
R1 97.6 (40/41) 87.1–99.9 57.9 (88/152) 49.6–65.9
R2 97.6 (40/41) 87.1–99.9 86.2 (131/152) 79.7–91.2
R3 92.7 (38/41) 80.1–98.5 99.3 (151/152) 96.4–100
aEach diagnostic value was calculated with 95% CI.
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pH is maintained throughout. This allows ampliﬁcation of the bacterial population,
thereby maximizing the release of POA into the extracellular environment while
preventing bacterial killing. As MODS-Wayne only evaluates the presence of POA in the
supernatant, there is no need to satisfy the culture conditions, including an acidic pH,
necessary to demonstrate PZA’s antibacterial activity. The advantage of using a neutral
pH is that acidity inhibits the growth of M. tuberculosis and therefore reduces the test’s
speciﬁcity (44). MODS-Wayne overcomes other limitations of the traditional DSTs for
PZA, in that there is no requirement for an isolate to be grown ﬁrst (indirect test), or for
a large inoculum size (3 to 5 mg) in order to avoid false-negative results (30).
MODS-Wayne reported a median turnaround time of 18.5 days (range, 14 to 29 days)
for PZA-susceptible isolates and 21 days (range, 14 to 25 days) for PZA-resistant isolates
for results in R3. Although the MODS-Wayne turnaround time was higher than that
reported for direct MGIT-PZA (range, 11 to 16 days), Demers et al. (45) reported that
41% (163/398) of the direct MGIT-PZA results were uninterpretable mostly due to
growth failure, and most of the indirect tests (i.e., classic Wayne test) require primary
isolation of the isolate ﬁrst, which means that from the time when the specimen was
collected until the susceptibility results were obtained, the turnaround time ranged
from 18 to 95 days. Total time from sample to results is in fact much shorter for
MODS-Wayne, which is a direct test.
The use of a composite standard where no good single standard exists has been
described (12). Using our composite reference standard (MGIT, classic Wayne test, and
pncA sequencing), we found that around half of the selected MDR-TB strains were PZA
resistant (30/57 samples [52.6%]), but few of the selected pansusceptible strains were
PZA resistant (4/101 samples [4.0%]). These ﬁndings are in agreement with rates
reported by other studies (3, 6, 20).
Both the classic and the quantitative Wayne assays (8, 28) evaluate PZase activity
using PZA concentrations ranging from 100 g/ml to 400 g/ml (21). In this study, we
used a PZA concentration of 800 g/ml in order to obtain a maximum signal without
compromising speciﬁcity. This concentration was established in a previous study
optimizing the assay, as it enabled us to most accurately discriminate isolates with
weak-positive Wayne activity (PZA susceptible) from those with negative Wayne activity
(PZA resistant) (our unpublished data). Compared to the classic Wayne test, MODS-
Wayne showed an agreement and kappa index of 93.8% and 0.79, respectively. Ten
isolates showed discrepant results, i.e., were PZA susceptible according to the classic
Wayne assay and PZA resistant according to MODS-Wayne; nine isolates clearly have
genuinely PZA-resistant phenotypes because they have mutations in pncA that are close
to the active site (Q10P and Q10R) or affect directly themetal-binding site (H51R and H57R),
both of which are associated with PZA resistance (7). Additionally, these isolates reported
PZA resistance by MGIT-PZA. This discrepancy may be attributable to misinterpretation
during the reading of the classic Wayne assay, as difﬁculty in the correct interpretation of
weak-positive samples has been reported as a limitation of this test (8, 29, 30). On the
contrary, the single wild-type strain that was falsely reported as PZA resistant by the
MODS-Wayne may have been be due to the lack of PZA addition during the incubation
period. This isolate was reported as PZA susceptible by MGIT-PZA.
Although MODS-Wayne does not evaluate pncA mutations, it had 96.9% agreement
and a kappa index of 0.90 with pncA sequencing. One disadvantage of molecular
methods is that interpretation of the results requires an understanding of the roles of
pncA gene mutations and PZase activity (4). Not all mutations in the putative promoter
or the pncA gene have been reported, and not all reported mutations are associated
with PZA resistance. Nevertheless, MODS-Wayne is a phenotypic test that indirectly
evaluates pncA mutations (i.e., mutations that affect pncA expression or impair PZase
activity) by detecting POA, the enzymatic product of the PZase. In this case, a mutation
database is not required to interpret the results. Six of 7 isolates harboring K48T
maintained PZase activity and were reported as positive by MODS-Wayne and PZA
susceptible by MGIT-PZA. K48T is an example of a mutation that is not associated with
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PZA resistance. More studies are necessary to understand the real effect of some
mutations that do not impair PZase activity on PZA susceptibility.
As a phenotypic test, MODS-Wayne depends on the growth of M. tuberculosis in
culture and its capacity to produce a detectable amount of POA. Our results showed
that the level of growth inﬂuenced the time to positivity on MODS-Wayne, and there
was also a trend in association of the bacillary load on smear microscopy with time to
results, although this did not reach statistical signiﬁcance. We hypothesized that a low
number of PZA-susceptible bacilli can lead to a negative result in the early reading
days, which can be considered false PZA resistance. This could be mitigated by using
a longer duration of culture prior to the addition of PZA to the assay, which would
increase the number of PZA-susceptible bacilli and give a positive MODS-Wayne result.
Our data show that the accuracy of MODS-Wayne (92% sensitivity and 99.3%
speciﬁcity) is comparable to that of other tests for PZA resistance detection (MGIT,
classic Wayne, and pncA sequencing). The MODS-Wayne assay and MGIT-PZA had an
agreement and kappa index of 95.3% and 0.86, respectively. The sensitivity and
speciﬁcity of the MODS-Wayne assay were optimal in R3 (92.7% and 99.3%, respec-
tively); although sensitivity was slightly higher in R2 (97.6%), our assumption is that
longer culture duration may permit a more accurate discrimination of the PZA-resistant
from the PZA-susceptible isolates. This will need to be conﬁrmed in future studies.
Finally, it is important to highlight that the MODS-Wayne assay lends itself to
incorporation into the standard MODS assay. This would generate a single unique test
that would be able to diagnose TB, MDR-TB, XDR-TB, and PZA resistance from the same
sputum sample with high accuracy and in a relatively short time.
In conclusion, here, we describe the MODS-Wayne test, a modiﬁcation of the standard
MODS method that is able to determine PZA susceptibility with high accuracy and in a
relatively short time. Although DST for most ﬁrst- and second-line TB drugs is available, PZA
susceptibility testing is not routinely performed despite widespread use of the drug
because of well-described difﬁculties in testing its activity in vitro. MODS-Wayne overcomes
these difﬁculties and also has the advantages of low cost and being easy to perform and
interpret. Thus, the MODS-Wayne assay offers the real possibility of introducing routine PZA
susceptibility testing in resource-constrained and/or high-TB-burden settings. This would
represent a major advance in the treatment of TB patients worldwide.
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